The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2–58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates . Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.

在这个使用 PET 扫描进行功能成像的时代，放疗 (RT) 在晚期霍奇金淋巴瘤 (HL) 治疗中的作用没有得到充分定义。SWOG-S0816 治疗了患有 ABVD+/- escBEACOPP 且无放疗的晚期霍奇金淋巴瘤患者。我们通过根据 HD15 PET + 残留病灶≥2.5 cm 标准模拟放疗使用，询问放疗是否可能使 S0816 中符合放疗 GHSG-HD15 标准的患者受益。接受者操作特征分析是通过改变辐射野内的疾病控制率和残留疾病的大小截断值来进行的。在 49 名 PET3+ S0816 患者中，使用三个残留病灶临界值（1.5、2.0 和 2.5 cm）并假设 80% 和 90% 的现场控制率，RT 会将 2 年 PFS 从 30.6% 提高到 50.2-58.1%。